Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant

Detalles Bibliográficos
Autores principales: Xia, Shuai, Chan, Jasper Fuk-Woo, Wang, Lijue, Jiao, Fanke, Chik, Kenn Ka-Heng, Chu, Hin, Lan, Qiaoshuai, Xu, Wei, Wang, Qian, Wang, Chao, Yuen, Kwok-Yung, Lu, Lu, Jiang, Shibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793821/
https://www.ncbi.nlm.nih.gov/pubmed/35087243
http://dx.doi.org/10.1038/s41422-022-00617-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793821/
https://www.ncbi.nlm.nih.gov/pubmed/35087243
http://dx.doi.org/10.1038/s41422-022-00617-x

Ejemplares similares